JP2021535140A5 - - Google Patents

Info

Publication number
JP2021535140A5
JP2021535140A5 JP2021510639A JP2021510639A JP2021535140A5 JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5 JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5
Authority
JP
Japan
Prior art keywords
antibody
naturally
antibody fragment
molecule
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510639A
Other languages
English (en)
Japanese (ja)
Other versions
JP7759805B2 (ja
JP2021535140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048677 external-priority patent/WO2020047176A1/en
Publication of JP2021535140A publication Critical patent/JP2021535140A/ja
Publication of JP2021535140A5 publication Critical patent/JP2021535140A5/ja
Priority to JP2025050991A priority Critical patent/JP2025098156A/ja
Application granted granted Critical
Publication of JP7759805B2 publication Critical patent/JP7759805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510639A 2018-08-28 2019-08-28 抗ｃｄ３抗体葉酸生物複合体およびその使用 Active JP7759805B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050991A JP2025098156A (ja) 2018-08-28 2025-03-26 抗ｃｄ３抗体葉酸生物複合体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723793P 2018-08-28 2018-08-28
US62/723,793 2018-08-28
PCT/US2019/048677 WO2020047176A1 (en) 2018-08-28 2019-08-28 Anti-cd3 antibody folate bioconjugates and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050991A Division JP2025098156A (ja) 2018-08-28 2025-03-26 抗ｃｄ３抗体葉酸生物複合体およびその使用

Publications (3)

Publication Number Publication Date
JP2021535140A JP2021535140A (ja) 2021-12-16
JP2021535140A5 true JP2021535140A5 (cg-RX-API-DMAC7.html) 2022-09-06
JP7759805B2 JP7759805B2 (ja) 2025-10-24

Family

ID=68051890

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510639A Active JP7759805B2 (ja) 2018-08-28 2019-08-28 抗ｃｄ３抗体葉酸生物複合体およびその使用
JP2025050991A Pending JP2025098156A (ja) 2018-08-28 2025-03-26 抗ｃｄ３抗体葉酸生物複合体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050991A Pending JP2025098156A (ja) 2018-08-28 2025-03-26 抗ｃｄ３抗体葉酸生物複合体およびその使用

Country Status (12)

Country Link
US (1) US12377294B2 (cg-RX-API-DMAC7.html)
EP (1) EP3844188A1 (cg-RX-API-DMAC7.html)
JP (2) JP7759805B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210063351A (cg-RX-API-DMAC7.html)
CN (1) CN111417655A (cg-RX-API-DMAC7.html)
AU (1) AU2019327456A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110647A1 (cg-RX-API-DMAC7.html)
IL (1) IL281076A (cg-RX-API-DMAC7.html)
MX (1) MX2021002301A (cg-RX-API-DMAC7.html)
SG (1) SG11202101875VA (cg-RX-API-DMAC7.html)
WO (1) WO2020047176A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348603B (zh) * 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2021173889A1 (en) * 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
JP5773382B2 (ja) 2010-12-29 2015-09-02 株式会社Sumco シリカガラスルツボ及びその製造方法
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
FI3322727T3 (fi) * 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
CN108348603B (zh) * 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
US12252534B2 (en) * 2016-02-04 2025-03-18 The Scripps Research Institute Humanized anti-CD3 antibodies, conjugates and uses thereof

Similar Documents

Publication Publication Date Title
JP2024123231A5 (cg-RX-API-DMAC7.html)
TWI250988B (en) Thrombopoietic compounds
US6177404B1 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
IL273285B1 (en) Anti- folate receptor alpha antibody conjugates and their uses
CN108066772B (zh) 靶向tacstd2的抗体与药物偶联体(adc)分子
CN110698565A (zh) 靶向肿瘤的CD38-pHLIP融合肽
JP2012116864A (ja) Ｇｌｐ−１化合物
JP2002543111A (ja) ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅
JP6876618B2 (ja) 治療目的のための抗体−ウレアーゼコンジュゲート
CN115175917A (zh) 药物缀合物及其应用
JP2022512746A5 (cg-RX-API-DMAC7.html)
SK57399A3 (en) Conjugates useful in the treatment of prostate cancer
CN115916801A (zh) 新型的α螺旋双性细胞穿透肽及其用途
US20030232760A1 (en) Conjugates useful in the treatment of prostate cancer
US10441628B2 (en) High activity tumour inhibitor and preparation method and use thereof
US10526385B2 (en) YAP protein inhibiting polypeptide and application thereof
CN113039194A (zh) 具有免疫调节特性的肽
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
JP6656661B2 (ja) プレキシンの結合調節剤
AU7432196A (en) Conjugates useful in the treatment of benign prostatic hyperplasia
JP2023520498A (ja) Ｇｌｐ－２誘導体またはその持続型結合体を含む放射線療法、化学療法、またはこれらの組合わせにより誘発された粘膜炎の予防または治療用薬学的組成物
WO2014044793A2 (en) Cd22-binding peptides
US20210214399A1 (en) Ph low insertion peptide and composition thereof
JP7179855B2 (ja) 低ｐＨ挿入ペプチド及びその組成物
US6274704B1 (en) Peptides derived from the heparin binding domain of fibronectin